Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma.

Jack Patrick GleesonFergus KeaneNiamh M KeeganEmin MammadovEmily HarroldAbdullah AlhusainiJeffrey HarteAustin Eakin-LovePhilip J O'HalloranStephen MacNallyBryan T HennessyOscar S BreathnachLiam GroganPatrick G Morris

Published in: Cancer medicine (2019)

In this retrospective study, reduced-dose bevacizumab schedule resulted in similar OS to standard-dose bevacizumab monotherapy with substantial cost savings. MGMT methylation appears to convey a survival benefit in the setting of bevacizumab treatment for progressive GBM.

Keyphrases

metastatic colorectal cancer
combination therapy
multiple sclerosis
open label
dna methylation
gene expression
randomized controlled trial
genome wide
clinical trial